NEW YORK, Aug. 2, 2024 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Allarity Therapeutics, Inc. (NASDAQ: ALLR) ("Allarity" or "the Company").The investigation focuses on whether the Company issued false and/or misleading statements and/or did not disclose information pertinent to investors.PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATIONOn July ...

NEW YORK, July 31, 2024 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Allarity Therapeutics, Inc. (NASDAQ: ALLR) ("Allarity" or "the Company"). The investigation focuses on whether the Company issued false and/or misleading statements and/or did not disclose information pertinent to investors. PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION On  ...

NEW YORK, July 28, 2024 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Allarity Therapeutics, Inc. (NASDAQ: ALLR) resulting from allegations that Allarity Therapeutics, Inc. may have issued materially misleading business information to the investing public.So what: If you purchased Allarity securities you may be entitled to compensation without payment of any out of pocket fees or costs through a c ...

NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Allarity and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] ...

NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Allarity Therapeutics, Inc. (“Allarity” or “the Company”) (NASDAQ: ALLR). Investors who purchased Allarity securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/ALLR. Investigation Details On July 22, 2024, Allarity filed a current report on Form 8-K with the SEC and disclo ...

Boston (July 26, 2024)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, announced that its Board of Directors has decided to postpone the Annual Meeting of Stockholders, which was originally scheduled for 10:00 AM Eastern Time today, July 26, 2024. On July 25, 2024, the Board, exercising its authority under the Company's bylaws, opted to delay the meeting to a future date, which w ...

Boston (July 26, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, announced that its Board of Directors has decided to postpone the Annual Meeting of Stockholders, which was originally scheduled for 10:00 AM Eastern Time today, July 26, 2024. On July 25, 2024, the Board, exercising its authority under the Company’s bylaws, opted to delay the meeting to a future date, which ...

NEW YORK, July 25, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether Allarity and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action]On February 6 ...

Allarity Therapeutics (NASDAQ:ALLR) stock is on the rise Wednesday as the clinical-stage biopharmaceutical company is encouraging its shareholders to vote in favor of a reverse stock split.Allarity Therapeutics put out a press release pushing for investors to approve the reverse stock split during an upcoming shareholder meeting. That meeting is set to take place on Friday.Allarity Therapeutics is also advising its investors to approve the reduction of its authorized shares alongside the reverse stock split ...

ATLANTA, July 24, 2024 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR) complied with federal securities laws. On July 22, 2024, Allarity disclosed that it received a Wells Notice from the SEC concerning "the Company's disclosures regarding meetings with the United States Food and Drug Administration (the "FDA") regarding the Company's NDA for Dovitinib or Dovitinib-DRP, which was submitted to the FDA in 2021." Followin ...